Prediction of Response to PEGINTERFERON and RIBAVIRIN Treatment in Patients With Chronic HCV Infection by Genetic Profile
Sponsor study identifier
observational
150
1 country
1
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
May 2006
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
We hypothesized that pretreatment nonresponder and responder liver tissue would show consistent differences in gene expression levels and that these differences could be used to predict treatment outcomes and this can obviate the need of the present therapeutic trial.We are interested in conducting a retrospective study using the data of patients suffering from chronic HCV infection who were treated in our department with a combination of PEGINTERFERON and RIBAVIRIN. All these patients underwent liver biopsy prior the treatment. Based on the clinical data available it is possible to determine the responders and nonresponders to this therapy.RNA will be extracted from the liver tissue and the expression of 5 genes(IFI15,IFI616,IFI1,OAS3,OAS2 )will be checked .The prediction power of the combination of these genes in differentiating responders from nonresponders will be determined.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2006
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 4, 2006
Actual (reported)January 6, 2006
Actual (reported)March 2006
Date type not reportedThis date has not been verified as actual or estimated.
May 2006
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Contact the study team to confirm eligibility.
Hadassah Medical Organization
Jerusalem, Israel
Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005 May;128(5):1437-44. doi: 10.1053/j.gastro.2005.01.059.
Yaron Ilan, MD
Hadassah Medical Organization
First Submitted
January 4, 2006
First Posted
January 6, 2006
Study Start
March 2006
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
May 2006
Estimated (date passed)Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 6, 2006
Record last verified: 2006-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: